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Abstract
This document presents a sectoral analysis of AI in health and healthcare for AI Watch, the knowledge service 
of the European Commission monitoring the development,  uptake and impact of Artificial  Intelligence for 
Europe. Its main aim is to act as a benchmark for future editions of the report to be able to assess the 
changes in uptake and impact of AI in healthcare over time, in line with the mission of AI Watch. The report  
recognises that we are still at an early stage in the adoption of AI and that AI offers many opportunities in the  
short term for improved efficiency in administrative and operational processes and in the medium-long term 
for clinical applications, patients’ care, and increased citizen empowerment. At the same time, AI applications 
in this sensitive sector raise many ethical and societal issues and shaping the direction of development so 
that we can maximise the benefits whilst reducing the risks is a key issue. In the global context, Europe is well  
positioned  with  a  strong  research  base  and  excellent  health  data,  which  is  the  pre-requisite  for  the  
development of beneficial  AI applications. Where Europe is less well placed is in translating research and 
innovation into industrial applications and in venture capital funding able to support innovative companies to 
set themselves up and scale up once successful. There are however noticeable exception as the case of the 
BioNTech that is leading the development of one of the COVID-19 vaccines. It should also be noted that in AI-
enabled health  start-ups,  many of them are in  the area of drug discovery,  i.e.  the domain of BioNTech.  
Investment  in  education  and  training  of  the  healthcare  workforce  as  well  as  creating  environments  for  
multidisciplinary exchange of knowledge between software developers and health practitioners are other key 
areas. The report recognizes that there are many important policy developments already in the making that  
will  shape  future  directions,  including  the  European  Strategy  for  Data  which  is  setting  up  a  common 
dataspace for health, a risk-based regulatory framework for AI to be put in place by the end of 2020, and the 
forthcoming launch of  the  Horizon Europe programme as well  the  Digital  Europe Programme with  large 
investments in AI, computing infrastructure, cybersecurity and training. The COVID-19 crisis has also acted as 
a booster to the adoption of AI in health and the digital transition of business, research, education and public 
administration. Furthermore, the unprecedented investments of the Recovery Plan agreed in July 2020 may 
fuel development in digital technologies and health beyond expectation. We are therefore at the junction of a 
potentially extraordinary period of change which we will  be able to measure in future years against the 
baseline set by this report.
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Executive Summary
This document presents a sectoral analysis of AI in health and healthcare for AI Watch, the knowledge service 
of the European Commission monitoring the development,  uptake and impact of Artificial  Intelligence for 
Europe. Its main aim is to act as a benchmark for future editions of the report to be able to assess the 
changes in uptake and impact of AI in healthcare over time, in line with the mission of AI Watch.
Europe’s global positioning
Within  the  global  landscape,  the  EU is  generally  well-placed  in  the  application  of  AI  in  the  health  and 
healthcare domains, somewhat behind China but at par with the USA. The research dimension is particularly  
strong in the EU, with research institutions accounting for about two thirds of all EU players in this field,  
compared to one third of players in China, and a relatively small proportion in the US, where developments in  
this field are dominated by commercial companies. In terms of areas of specialisation, in the EU and the USA,  
most of the activity concentrates on diagnostics and health technology assessment. China has a strong focus 
on diagnostics, which includes image recognition technologies for which China is a worldwide leader.
Social and ethical impact of AI in health care
AI systems offer opportunities in medical applications in fields such as oncology, genetics and neurosciences,  
but  also  present  possible  risks  and  ethical  questions  raised  by  their  implementation.  AI  is  a  dual-use 
technology: it can be used for positive applications as well as very controversial or unethical ones. Beneficial 
applications  include software for decision support to improve diagnostic efficiency,  but harmful areas  may 
include new tools for bioterrorism. In between these two extremes, there are many applications analysed in 
the report that display varying degree of benefits and risk, and a social-controversy index is used to flag the  
potential levels of concern.
Main findings from the data analysis
Scientific medical literature: We observed a marked increase of publications in AI and healthcare in the period 
2012-2014 and since 2018. The COVID-19 pandemic in 2020 is giving further impulse to the research in this  
domain. Similarly, the analysis of the EU R&D projects shows a growth in health and healthcare projects since 
2015 and, in combination with AI, since 2017.
Industrial sector: The number of patent applications increased after 2012 and its pace accelerated after 2014, 
particularly in China and the USA. European companies like Siemens and Philips are among the top players,  
following the South Korean Samsung electronics, which however patens many sensing devices that can also 
be used in health-related applications, rather than patents specifically conceived for health purposes.
The  percentage  of  venture  capital  (VC)  investment  directed  towards  AI  and  health  startups  has  also 
undergone a fast expansion: from 2-3% in 2012 to 15% in 2017. The vast majority of this VC investment 
goes to the USA (74%) compared to Europe (14%). This confirms that whilst Europe is well positioned in terms 
a strong research base and excellent health data, it is less well placed in translating research and innovation 
into industrial applications and in VC funding supporting innovative companies to set themselves up and scale 
up. There are however exceptions, as in the case of the BioNTech company, leading the development of one of 
the COVID-19 vaccines. 
Key Conclusions
We highlight, in conclusion, three axes likely to acquire relevance in the coming years: In the short term, the 
lower-hanging fruit of AI applications in health care is represented by operational applications, streamlining 
tasks and processes, which are at a mature stage and are already deployed in several industrial sectors. In  
the medium term, the priority is to increase access to health data and ensure its interoperability.  This is  
critical to concretely allow healthcare actors to develop and use AI technologies. Europe is well positioned in  
terms of the wealth of health data gathered by the Member States but to unleash this potential needs to 
implement the common data spaces envisaged by the European Strategy for data.  Finally, in the long term, AI  
applications cannot thrive in the healthcare domain without the upskilling of healthcare practitioners at all  
levels.  Therefore,  data  science  should  become  part  of  their  education  and  training,  so  that  they  are  
empowered to become active players in the development of AI solutions and not just passive users.
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Foreword
This report is published in the context of AI Watch, the European Commission knowledge service to monitor 
the development, uptake and impact of Artificial Intelligence (AI) for Europe, launched in December 2018.
AI has become an area of strategic importance with potential to be a key driver of economic development. AI  
also has a wide range of potential  social  implications.  As part  of  its  Digital  Single Market Strategy,  the 
European Commission put forward in April 2018 a European strategy on AI in its Communication "Artificial  
Intelligence  for  Europe"  COM(2018)  237.  The  aims  of  the  European  AI  strategy  announced  in  the 
communication are:
 To boost the EU's technological and industrial capacity and AI uptake across the economy, both by
the private and public sectors
 To prepare for socio-economic changes brought about by AI
 To ensure an appropriate ethical and legal framework.
Subsequently, in December 2018, the European Commission and the Member States published a “Coordinated  
Plan on Artificial Intelligence”, COM(2018) 795, on the development of AI in the EU. The Coordinated Plan  
mentions the role of AI Watch to monitor its implementation.
AI Watch monitors European Union’s industrial, technological and research capacity in AI;  AI-related policy  
initiatives in the Member States; uptake and technical developments of AI; and AI impact. AI Watch has a 
European focus within the global landscape. In the context of AI Watch, the Commission works in coordination 
with Member States. AI Watch results and analyses are published on the AI Watch Portal ().
From AI Watch in-depth analyses we will be able to understand better European Union’s areas of strength and 
areas where investment is needed. AI Watch will  provide an independent assessment of the impacts and 
benefits of AI on growth, jobs, education, and society.
AI Watch is developed by the Joint Research Centre (JRC) of the European Commission in collaboration with 
the Directorate-General for Communications Networks, Content and Technology (DG CONNECT). 
This report presents a sectoral analysis of AI Watch focused on the uptake of AI in the health and healthcare  
sectors. Its key aim is to act as a benchmark for future editions to be able to assess the changes in uptake 
over time in line with the mission of AI Watch. The report is based on the methodology described in Craglia et  
al. (2020) which centred on four components: 
1. Scanning and analytics
2. Partnerships
3. Reviews
4. Longitudinal panel studies.
The restrictions to travel and meetings imposed by COVID-19 limited the ability to establish the longitudinal  
panel necessary for further studies of impacts. These will be available in future editions of this report. This  
first edition therefore focuses mainly on the outcome of the first three strands of the methodology, and in 
particular scanning and analytics and reviews. 
Another report on AI and Health (Barbas et al. 2020) is being published by the JRC focusing on the strategic  
autonomy of Europe in this key value chain. The synergy between the two reports has been assured through 
cross authorship and reference.
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1. Introduction
The potential of AI applications in health care is the object of considerable interest. Governments in Europe, 
but also other countries such as Japan and India, are giving AI applications in health a high priority due to 
factors such as aging population and shortage of health care professionals (McKinsey, 2020). As an example,  
the  national  strategies  of  Belgium,  Cyprus,  Denmark,  Finland,  France,  Germany,  Hungary,  Italy,  Latvia, 
Lithuania, Malta, Poland, Spain, Sweden, and the UK all refer to healthcare as one of their priority sectors [van  
Roy, 2020]. A JRC AI Watch survey of 200 European AI projects in the public sector (Misuraca 2020), found  
that health-related ones are the  third most  numerous (35) and,  in  this  cohort,  22 initiatives are geared 
towards increasing performance and effectiveness of such services. Furthermore, in a survey of 18 European  
countries, the health sector ranked first as the policy domain to prioritize in the future (Misuraca, 2020).
The European Commission has also identified health as one of the key applications for AI in a number of 
policy  documents  reviewed  in  Section  5,  and  the  High-Level  Expert  Group  established  by  the  European 
Commission in 2018 as part of its AI Strategy (EC, 2018a) has also included health as one of the three 
sectors  for  which  it  has  provided  specific  recommendations  on  investment  (the  others  being  advanced 
manufacturing, and public administration). 
Whilst the level of interest and the number of pilot projects and experimentations are growing, the level of  
diffusion is still relatively low and most projects are just at an initial stage to “test the water”. As an example, 
a  survey1 by  the  Observatory  on  Digital  Innovations  in  Health  of  the  Politecnico  di  Milano  in  2018  of 
practitioners and managers of health institutions in Italy revealed that only 20% of the respondents identified  
AI as a priority and that the overall level of investment in AI was rising but was still very low (€ 7m) against 
an overall expenditure for digital innovation in health of some € 1.4 bn. in 2018. 
Public sector organisations are understandably more cautious in adopting AI, while there is greater interest in  
the commercial sector as well as research as we show in this report. Notwithstanding this increasing interest,  
the application of AI in health is not without its critics: for example, in a recent article in Nature Medicine  
(Panch, 2019), the authors express vigorous skepticism about using, at this point in time, AI algorithms and  
models  in  the  front  lines  of  clinical  practice,  identifying  the  challenges  of  both  a  cultural  change  and 
infrastructural upgrade.
While clinical  applications of AI are perhaps the most visible,  we adopt in this  report a wider taxonomy,  
borrowed  from  the  American  Hospital  Association  report (AHA,  2019b),  featuring  four  big  areas  of 
applications: Administrative, Financial, Operational and Clinical. These areas convey a more complete picture  
of the AI potential in health services, such as hospitals. 
Following this introduction, Section 2 assesses the position of Europe on AI and health with respect to the 
global landscape, building on the AI Watch report on the AI global landscape by Samoili et al. (2020). Section  
3  focuses  on  technology  availability  levels,  Sections  4  and  5  review  the  increasing  interest  in  AI  and  
health/healthcare in the scientific and research domains, Section 6 focuses on industrial innovation through 
the analysis of patents and venture capital, Sections 7 and 8 give examples of local and European initiatives,  
and Section 9 draws the conclusions.  
2. Global positioning
The AI  landscape based on the Techno-economic segment (TES) methodology described in Samoili  et  al.  
(2020) identified just over 31,000 key players active in the AI global scene from 2009 to 2018, of which 
28,000 are firms and 3,000 research institutions. A key player  can be a company, research institution or 
governmental authority involved in one or more of the following economic activities: R&D processes -research 
and  innovative  developments-,  general  economic  processes  -industrial  production,  marketing  and  other 
services-, firms funding –venture capital funds or other types of investment (De Prato et al. 2019). 
Players with same names, but different geographic location, as e.g. multinational enterprises with several  
branches, are considered as distinct players as they may engage in different sets of activities with different  
partners.  Therefore,  when  considering  the  number  of  activities,  they  are  treated  separately,  but  when 
considering the number of players they are merged to avoid double-counting.
Figure 1 shows the overall geographical distribution of identified AI players. As shown, the US has the largest 
number of players, followed by the EU and China. The EU is notable for the large number of players active in  
1 https://www.osservatori.net/it_it/osservatori/comunicati-stampa/spesa-sanita-digitale-italia 
7
the European Union research programmes. When compared to their national GDP, Israel, Canada and South  
Korea stand out for their number of players. When filtering these players to search for those active in both AI  
and health, we found some 2000 players, i.e. about 6% of the total distributed as shown in Figure 2. 
Figure 1: Top 10 world geographic areas by number of AI players:  
Absolute number and Relative to GDP(€bn in PPS), 2009-18
Source: Samoili et al. 2020a
Figure 2: Number of AI and Health players by geographical macro-area and type of players.
Source: Barbas et al. 2020. 
Note: a governmental institution is a governmental research organisation or institution that, as in the definitions of players, has 
participated in one or more of the following economic activities: R&D processes, industrial production and marketing, specific AI-related 
services.
The figure shows that China is the most active country in AI and health, followed by the EU27 (to note that in 
Figure 1 the EU included 28 Member States, as UK was still a Member State at the time) and the US. What is  
very  noticeable  is  that,  in  the  EU,  almost  two  thirds  of  players  are  involved  in  research,  against  the  
approximately one third in China, while in the US the number of research institutions involved in AI and health 
is negligible compared to the industrial players. Looking at the numbers of players weighted by GDP, the UK 
stands out as having the greatest number followed by South Korea. 
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When  focusing  on  the  number  of  players  active  in  research  (i.e.  submitting  abstracts  in  top  level  AI  
conferences, participating in research projects or patenting) Figure 3 shows the situation across all AI players, 
while Figure 4 focuses on the ones active both in AI and health. 
Figure 3: Global AI players in R&D
Source: Samoili et al. 2020a
Figure 4: AI & Health players in R&D
Source: Barbas et al. 2020
Comparing the two figures, it is worth noting that China is way ahead in the global landscape for all AI players  
(Fig. 3) largely because of the large number of patents it files (Almost 60% of the world total, see Sec. 6.2)  
while in the AI and Health domain, its position is still in front but not so dominant. Furthermore, the EU27  
shows a very  strong research component that  puts  it  ahead of  the  US insofar  the number of  research 
institutes is concerned (Fig. 4). At the same time if we compare Figure 4 with Figure 2, it is also clear that in  
the US the sector of AI and Health is strongly dominated by commercial firms that may be doing internal R&D 
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without being very visible in the research community. Therefore, it is not so surprising that when focusing on  
the R&D sector, the US does not seem to feature so strongly. 
2.1 Analysis by health topic 
The profiles of the key players in China, EU, and the USA, using or developing AI for health were analysed with  
respect to the health subtopics summarized in Table 1. The methodology and full list of topics included in  
each group are described in Barbas et al. (2020).
Table 1: Application categories in AI and Health
Health sub-topic Topics  included (examples)
COVID-19 studies and activities related to pandemics and contact tracing apps
Sovereignty cybersecurity, data governance, stakeholder involvement
HTA health technology assessment
Prevention wearables, hospital info systems, cardiac devices 
Diagnostics screening, diagnostics, image analysis, health data analysis
Public health big data analysis, social medicine 
Devices modelling of physical properties, device design and development
Pharmaceuticals drug and vaccine development.
Figure 5 compares the profile of the three key macro-areas based on the health sub-topics of Table 1 by  
looking at the activities in which the players have been involved. 
An activity can be research and innovation processes, industrial production, trade and marketing, specific AI-
related services, firms funding (venture capital funds or other types of investment). These activities may be  
either stated explicitly, e.g. inside the description of company activities in business registers, or derived from 
analysis  of  their  R&D activities,  e.g.  inside  text  of  conference proceedings,  research  projects  or  patents.  
Furthermore, the number of activities includes:
 Industrial Capacity: number of activities related to firms (production, trade, investments),
 Innovative (disjoined) potential: number of patents filed by single applicants – carrying “potential” for  
development, 
 Inner innovative network capacity:  number of internal (same geographical area)  collaborations in 
filing patents – shows effectiveness of internal innovation network,
 R&D (disjoined) potential: number of single-authored research publications in top AI conferences,
 R&D network capacity: number of internal (same geographical area) collaborations for publications in 
top AI conferences – effectiveness of internal research network,
 Strategic Worldwide Network Influence: number of external collaborations across geographical areas 
– measures the degree of centrality of individual macro-areas and their capacity to influence the 
overall AI & Health ecosystem network,
 Knowledge accumulation (with/without Horizon 2020 projects): access to information and knowledge 
for individual macro-areas through their own activities and all types of collaborations (Barbas et al.,  
2020).
As shown, China is particularly active in technologies and methods related to diagnostics  which includes 
image processing/recognition while the EU and the US have similar profiles with Europe having a slightly  
stronger focus on diagnostics and the US a stronger focus on prevention methods and technologies.
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Figure 5: AI Activity by health topic 
EU China
USA
2.2 Regional specialisation
Figure 6 uses the same categories of Figure 5 to show the geographical specialisation by regions. As shown, 
all the top regions are in China with a large focus on diagnostic equipment and methods, followed by Seoul in  
South Korea, California and New York in the USA. European regions that emerge are Cataluña, London and  
Paris in the lower end of the graph. The data here is however strongly influenced by the number of patents  
filed in China (see also Section 6). 
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Figure 6: R&D activities by region and AI & Health topic
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3. Technology availability of AI in medicine and healthcare
Gómez-González and Gómez (2020) provide an updated review of the current and future applications of AI in  
the area of medicine and healthcare, based on an analysis of over 600 references representing the state-of-
the-art research and technology, including software, personal monitoring devices, genetic tests and editing  
tools, personalized digital models, online platforms, augmented reality devices, and surgical and companion 
robotics.
Figure 7 presents a ‘visual overview’ of this review, including well-established applications such as the use of 
algorithms to support medical diagnosis, robots in surgery or conversational platforms (‘chatbots’) for patient  
assistance. In the figure, the different applications are assigned a Technology Availability Level (TAL) scale,  
presented in Table 2. TAL provides a qualitative description of the degree of availability of a technology in a  
numerical scale in 10 steps (levels) ranging from 0 (unknown status, not considered feasible) to 9 (available 
for the general public).  We observe in the Figure that applications such as algorithms for computer-aided 
diagnosis  or  imagining  tools  have  a  high  TAL  value  while  others  such  as  mind  reading  or  whole-brain  
simulation are still immature according to this scale. The TAL scale is similar in format (and related) to the  
standard ‘Technology  Readiness  Level’  (TRL)  scale  commonly  used  to  assess  research  and development 
figures, but it is based on published references (in scientific and academic literature, industrial or corporate  
reports, and in general media citing sources considered to be reliable according to standards). These types of 
scales are useful to convey practical information about the closeness to the market of a given technology. 
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AI systems offer opportunities in medical applications in fields such as oncology, genetics and neurosciences,  
but also present possible risks and ethical questions raised by their implementation. This balance between 
benefits and risk is represented by the ‘controversy level’ in Figure 7. This level ranges from ‘positive’ or  
beneficial  applications  of  AI  such  as  software  for  decision  support  to  improve  diagnostic  efficiency,  to 
‘negative’  or  harmful  areas  such  as  new  tools  for  bioterrorism or  the  possibility  to  engineer  biological 
weapons targeted against certain populations. 
There are many controversial issues as the same technology can be used for positive applications as well as  
very  controversial  or  unethical  ones  (dual-use  technology).  For  example,  genetic  editing  can  eliminate 
inherited defects but could be used to create “designer” babies, while neural interfaces and neurostimulation  
can help control prostheses but cold also become a vehicle manipulating neural signals and limiting free will  
(Gómez-González and Gómez 2020).
Table 2: The Technology Availability Level (TAL) scale
TAL Score Status of viability of the technology.
TAL 0 Unknown status. Not considered feasible according to references.
TAL 1 Unknown status. Considered feasible according to related, indirect references.
TAL 2 General/basic idea publicly proposed.
TAL 3 Calls for public funding of research and development (R&D) open.
TAL 4 Results of academic/partial projects disclosed.
TAL 5 Early design of product disclosed.
TAL 6 Operational prototype/'first case' disclosed.
TAL 7 Products disclosed but not available.
TAL 8 Available products for restricted (e.g. professional) users.
TAL 9 Available for the public.
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Figure 7: A visual overview of the classification of AI and AI-mediated technologies in Medicine 
and Healthcare according to their ethical and social impact. 
Source: Gómez-González and Gomez, 2020.
Note:  SW:  software,  AR:  augmented  reality,  VR:  virtual  reality,  IoT:  internet  of  things.  
TAL: Technology Availability Level.
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4. Scientific Research
4.1 PubMed Data Analysis
Starting from the medical literature, we have analysed all the citations and abstracts of the papers published  
in PubMed, around 30 million since 2010, the world’s largest and most up-to-date source of medical scientific 
articles. Pubmed represents a formidable source of scientific literature in medicine, covering the United States 
and most other countries for articles published in English. 
In  Fig.  8,  we  depict  the  number  of  daily  published articles  which  contain  the  words 
covid/coronavirus/pandemics since December 2019 While the number of articles on coronavirus averaged at  
about 10 a day  up to the beginning of February, it started increasing in mid-February to almost 1000 articles 
per day, and has plateaued since June 2020. The reason can be attributed to several reasons - from lengthy 
data collection for the articles to shifting focus of scientists involved in other strands of research down to 
saturation of research capacity from June 2020 onwards. On the other hand, the sheer quantity of available 
data allowed data-driven analytics  and we see the  first  articles   (black dots  in  Fig.  8)  utilizing artificial 
intelligence, machine and deep learning and natural language processing being published since April 2020 
and increasing ever since. Even with flattening curve of the COVID-19 related articles, the number of articles  
referring to AI methods still increases.
Figure 8: Number of publications on AI and COVID Jan-November 2020
Source : JRC based on PubMed data
Looking  at  the  10-year  period  since  2010  in  Figure  9,  the  first  cluster  of  papers  discussing  AI-related  
technologies  in  PubMed  appears  in  2012-2014.  The  strongest  concepts  emerging  are  ‘data  mining’, 
‘algorithms’, ‘electronic health records’ and ‘natural language processing’. After a hiatus in the years 2015-
2017,  two other  clusters  are visible in  2018-2019:  the first  is  characterised by keywords ‘machine/deep 
learning’, ‘telemedicine’ and ‘delivery of health care’; while the second cluster includes ‘precision medicine’,  
‘electronic health records’ and ‘algorithms’. In the first four months of 2020, the range of topics co-occurring 
with AI is much wider, including concerns, such as ethics, and new applications (e.g. ‘critical care’), alongside 
pandemic-related keywords. The pattern above is also confirmed when looking to the overall growth of AI-
related publications in Scopus (Fig. 10), where in 2015, the curve becomes steeper as a consequence of the 
increasing traction of deep learning.
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Figure 9: Publications mentioning AI in the 2010-2020 in ln scale
Source: JRC based on  PubMed data
Figure 10: Papers published per year featuring words related to artificial intelligence 
in Scopus-indexed publications.
Source: JRC based on  PubMed data
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Digging further into the AI and health articles’ topics, we used the Medical Subject Heading (MeSH) thesaurus,  
by which PubMed articles are tagged. The huge advantage of this thesaurus is its hierarchical structure that  
allows for finding categories by aggregating the term trees to which the terms pertain. 
The 1972 terms found in  the 1640 PubMed articles  referring to artificial  intelligence,  machine and deep 
learning and natural language processing can be used to understand better the dynamics of AI uptake for 
medical research.  
Figure 9 shows two distinct types of the keywords, on the left - the concepts on "how" - the methods, and on  
the right, those on "what" - the application domains. The terms describing applications are 10-15 times less  
frequent simply because there is substantially less AI and supportive methods than the areas of application 
and thus the "what" keywords get diluted when cardinality of terms is the main criteria. 
The "application domain" plot (Fig.9 right) has an eye-catching cluster on coronavirus/pneumonia which is new 
in 2020. The 2020 pandemic-related abundance of data created opportunity to massive application of the AI 
methods. Critical care gets boost in 2020 as well but there has already been AI applied traditionally. Most  
striking difference is the 2020 vs 2019 research focus. Since we have used PubMed 2020 data until end of  
October 2020, we can see how research in several domains (e.g. computer diagnosis, pilot projects radiology,  
biomarkers, ...) has been superseded by the COVID-19 related research, which is also demonstrated in the  
Figure 8. 
The “methods” plot (Fig. 9 left) shows two large groups of methods. First is the "traditional" one based on 
databases, data mining and massive big data on the top, which has a long tradition in medical research. The  
second domain on the bottom shows the increase of novel approaches based on data science and smaller 
data sets, e.g. coming from cohorts.
To  see  the  whole  picture,  we  have  further  taken  advantage  of  the  hierarchical  structure  of  the  MeSH 
thesaurus, which, as aforementioned, allows for finding categories by aggregating the term trees to which the  
terms pertain. We have aggregated all 1972 terms found into super-categories (Fig. 11), where the numbers 
indicate the articles featuring a specific term every year.  There are five main clusters of terms as found by 
hierarchical agglomeration: the two obvious outlier clusters of common elements and infrastructure and three 
clusters grouped together by the speed of development. In this latter group, the green top category is the 
steady  development  group  that refers  to articles  on  symptoms,  infections,  neoplasms,  and nervous  and 
cardiovascular diseases, technologies including IoT.
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Fig 11: Clusters created by aggregation of MeSH categories.
Source :JRC based on  PubMed data
18
Coming to the most active journals and venues in the field of AI and health, we also used the publication date  
and journal name data to highlight the top ones. As selection criterion, we picked the journals and scientific 
conferences that have published at least 15 articles on AI and health in the 2010-2020 period. 
In Fig. 12, we can see the 18 journals and conferences matching the criteria sorted by the overall number of  
relevant articles. Most articles have been published in the Studies in health technology and informatics and 
presented in the American Medical Informatics Association (AMIA) Symposium.
Figure 12: Top journals and conferences in AI and health in the 2010-2020 period
Source :JRC based on PubMed data
In summary, the analysis of PubMed, which is the most comprehensive source of medical publications in the  
open domain shows a steady increase of articles featuring AI since 2012, with a significant acceleration since 
2017, which is in line with the increase in the number of AI and publications in all domains as we see in  
Scopus.  (Fig  10).  The  Covid-19 pandemic  has  given  further  impetus  with  published  articles  and citation 
increasing by 3 orders of magnitude in 2020 form around 10 to about 100 per day.
4. 2 Highlights from the literature
AI applications hold a significant potential for enhancing and streamlining existing tasks in medical practice  
and creating new opportunities, for instance giving patients more control over their health. In this section we 
briefly summarize some of those opportunities along with some challenges, highlighted in the literature, both 
for patients and health care practitioners, stemming from the introduction of AI in the healthcare.
4.2.1 Opportunities
Support to Health care professionals   AI applications can support healthcare professionals in fields from 
radiology  to  mental  health  (Topol,  2019a).  Image  processing  with  deep  learning  algorithms  over  large 
datasets can provide more accurate and faster assessment of X-rays, CT scans and images. Furthermore, 
natural language processing and knowledge management can be used to build sophisticated clinical decision 
support systems which can match symptoms to the related illnesses and suggest treatment, drawing on large 
corpora of medical documents and texts.  Furthermore, the ability of AI to learn patterns in time-series of 
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data is used in an array of smart wearables that, for instance, monitor blood sugar levels and administer  
insulin accordingly.
Beyond the purely clinical standpoint, there is an increasing awareness of the impact AI can have on the 
whole health system particularly for administrative and operational tasks.  For example,  Rajkomar,  (2019) 
analyses applications such as patient triage and streamlining billing. The technologies involved in these cases  
are  speech  recognition  and  chatbots,  which  are  also  very  powerful  in  mental  health  applications, 
recommender systems and process optimization.  AI technologies to make workflows more efficient, such as  
optimising appointments scheduling or stocks managing, are often very mature. They can leverage algorithms 
that have been operational since the nineties and therefore, as noted by AHA (2019b), could be the low-
hanging fruit for AI deployment in healthcare in the short term.
Support to Patients   On the patients’ side, AI applications can extend their control over their health and 
wellbeing  (Gómez-González,  and  Gomez  2020;  McKinsey,  2020)  through  telemedicine.  In  chronic  care 
management, for instance, medication compliance can be enhanced by mobile apps suggesting the treatment 
in a timely manner and alert systems powered by computer vision can support patient oversight. Systems as  
these can help reduce the need for  assistance or  hospitalization,  allowing the patient to  stay for  longer 
periods in a familiar environment, and can also provide physicians with a comprehensive bulk of data on the  
patient’s  condition.  Furthermore,  smart  wearables  such  as  insulin  pumps  or  portable  electrocardiogram 
devices can help manage ailments such as diabetes and cardiac diseases, preventing critical episodes. 
Empowerment for patients from AI can also come in the form of information (Gómez-González and Gomez, 
2020). Symptom checkers can give an immediate assessment to the patient, possibly avoiding long waiting 
times in emergency rooms. Such tools, together with affordable genome-sequencing tests, can lead to a much 
more informed patient, also reducing the ‘information asymmetry’ between patient and the doctor. Internet 
platforms dedicated to health contribute to such awareness of the patient, with the danger, however, of being  
exposed to sometimes erroneous and unreliable information. 
Synergy between doctors and developers Most AI solutions and applications are developed in research 
centers and companies to be then deployed in the clinical workflow (McKinsey, 2020). However, as detailed 
further in the following sections, building models drawing from the domain knowledge of clinicians could 
dramatically improve their quality and, to this end, an interdisciplinary setting between computer science and 
medicine should be envisioned for their development (McKinsey, 2020, Topol, 2019a, AHA, 2019a, Bortolin,  
2020). Practical examples of knowledge transfer from the computer science community exist in the medical 
literature: for instance, Rajkomar (2019) articulates the conceptual flowchart of a supervised learning model 
and a list of questions to assess the type of model required to tackle a given problem through the lens of AI. 
On this synergy between the practitioners and the ‘machine’, Topol (2019a) draws inspiration from the five 
levels  of  automation  defined  by  the  Society  of  Automotive  Engineers  (SAE)  for  vehicles:  with  Level  0 
corresponding to no automation at all, an unassisted human driver, up to Level 5 being full control by an  
automatic system, without possibility of human intervention or backup. In their assessment, medicine will 
likely plateau at Level 3, i.e. a conditional automation with human oversight over algorithms’ outputs, given 
the high social and ethical stakes. 
4.2.2 Challenges
The nexus  between AI  and health  care  is  characterised by  conflicting  priorities,  such  as  the  paramount  
importance of data privacy against the necessity of aggregating masses of data to train models accurately.
Technical From a technical standpoint, many  scientific papers featuring AI applications for healthcare are 
often in their early stage, carrying a number of methodological flaws noted in the literature (Topol, 2019a, 
Panch et al., 2019, Ghassemi, 2019). 
Firstly, there is concern over AI models that are based on small and statistically biased datasets, which can 
critically  hinder  their  accuracy and reliability.  Algorithmic  bias can be introduced,  for  example,  by under-
represented cohorts of patients or,  for supervised learning,  by inconsistency in labelling the training data 
(Ghassemi, 2019). This last step, relying on human experts discerning signals of the disease in the data, is  
pivotal for the quality of the AI model’s output. However, as clinicians’ assessment may vary, techniques from 
unsupervised learning can be deployed to mitigate labelling uncertainty.  To counter data paucity,  dataset 
sharing should be a desirable practice and, in this regard, the COVID-19 emergency already catalysed the  
emergence of dedicated platforms. “Data against COVID”2, for instance, is an exemplary initiative matching 
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data  brought  by  practitioners  and expertise  brought  by  data  scientists.  The  development  of  a  European 
common data space for health envisaged by the European Strategy for Data (EC, 2018b, EC, 2020a) is also a  
very important step in this respect. 
Secondly, the quality of the studies themselves is of paramount importance: Nagendran, (2020) and Liu et al.,  
(2019) performing a review of deep-learning applications in medicine, identified in their sample a majority of 
studies of poor statistical design. Some of the flaws included not using randomized trials, not adhering to 
existing guidelines and hindering reproducibility by not sharing code and datasets.  This lack of quality is  
particularly pernicious when paired, as the authors remark, with overpromising language opening the door to 
misinterpretation and fuelling the hype around AI in medicine.
Incorporating domain knowledge is another fundamental ingredient to have an efficient deployment of AI  
solutions. As mentioned earlier, the design of an AI model needs to incorporate the expertise of both computer 
scientists and medical practitioners to make sense of the data correctly . A promising example of this virtuous 
synergy emerged among COVID-19 AI applications. Shan et al. (2020) used a human-in-the-loop approach,  
alternating rounds of training and manual labelling of CT scans. Both the AI model and the expert labelling  
process were improved by this protocol, demonstrating the effectiveness of such hybrid approach.
Last but not least, further development of the health IT infrastructure is needed, with a particular focus on 
interoperability (Topol, 2019b). Most existing medical data is not “AI-ready” for algorithm development, or of  
high enough quality, for example often not exchangeable, difficult to process or interpret and error-prone. The 
electronic health record would constitute a formidable source of patient-level data for AI development, but it  
is available in only a few OECD countries, where national data are organised following a “one patient, one 
record” criterion and are standardised and interoperable (OECD, 2020). Nevertheless, as pointed out by Topol  
(2019b), the implementation of the health care record and of a sustainable infrastructure are the necessary  
foundations for delivering on AI in health care.
Social and ethical issues The  caveats  raised  by  AI  technologies  in  healthcare  extend  their 
ramifications  far  beyond  the  technical  ones.  Gómez-González  and  Gomez  (2020)  provide  a  high-level 
overview of the ethical and social implications, building on the analysis of more than 600 scientific references.  
They identify three overlapping groups of implications: common aspects to the use of AI at large (e.g. security 
and anonymity), aspects of particular relevance for healthcare (e.g. empathy) and ethical issues related to 
applications such as gene editing and bio-terrorism. 
The first group includes most of the challenges mentioned in the technical paragraph above which become 
more  important  in  healthcare  given  the  sensitivity  of  the  data  involved  and  the  possibly  catastrophic 
implications of errors and failures.
The second group considers the human aspects of medical practice such as the relationship between doctor  
and patient which is based not just on professional knowledge but also on empathy and trust, both of which  
are possibly  affected by the introduction of  AI  in  clinical  practice.  The impacts can be either  positive or 
negative depending on how the process is handled: for instance, empathy can be enhanced by streamlining 
cumbersome and repetitive administrative tasks and freeing up time for face-to-face interaction with the 
patient. On the other hand, empathy may be reduced in the context of telemedicine, where long-distance 
monitoring and assistance reduces human contact. Furthermore, in the context of online tools for symptom 
checking, it is often difficult for a patient to discern the pertinent information and interpret it correctly without 
the skills of a trained doctor.  These tools could also exacerbate inequality: digital literacy is a prerequisite for  
their use, and seeking health information online varies strongly with education, with those less educated also  
being  less  able  to  engage  in  such searches  (EC,  2019)  and in  Europe 30% of  citizens  declared feeling 
uncomfortable  with  their  ICT  skills  (Eurobarometer,  2020).  Therefore,  the  opportunities  for  patient 
empowerment tend to empower those who already are in a better position and leave further behind the  
disadvantaged groups. This was also observed in the lock-down response to the COVID-19 pandemic of 2020 
which exacerbated inequalities for the elderly, the young, and disadvantaged groups (Craglia et a. 2020). 
The third group of issues focuses on the ethical dilemmas of applications that have potentially dual effects.  
They include for example, the possibility of reading and decoding human brain signals which may challenge 
the very definition of free will if tampered with,  but also offers impaired patients the possibility to directly 
control their prosthetic limbs through interfaces with their neural system.
Regulation As Gómez-González and Gomez (2020) observe, no AI technology is good or bad in 
an absolute sense; however, as some of these do have the potential to be harmful, it is necessary to regulate 
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the introduction of AI in healthcare, as in other sensitive areas, with a risk-based approach able to reduce 
negative effects whilst allowing innovative and beneficial applications to thrive. This is the approach  proposed 
by the European Commission in its White Paper on AI (EC, 2020b) that launched a wide consultation on its 
risk-based approach to AI regulation with a view to propose legislation in the second half of 2020. 
Beyond health data, regulatory barriers  may slow down the AI diffusion in health:  for example, apps and 
software for health application are treated as medical devices and vetted through the same strict process for 
general medical devices. The length of this process is, however, often incompatible with the fast development 
in the field of smart health; therefore, according to (EASME, 2019), a streamlined approval process for AI  
applications should be envisioned, also considering the different interaction with a patient that AI solutions 
may have with respect to more traditional medical devices (EASME, 2019).
5. Horizon 2020 Research projects
Research is one of the main areas of European strength, as was shown in Figure 4. For this reason, we have  
analysed the over 30,000 research projects funded by the Horizon 2020 R&D programme of the European 
Union in 2014-21. The project descriptions available in CORDIS, the EU public database of research projects ( ) 
were analysed for projects related to AI, health and healthcare. The problem is, of course, that the human 
language is a highly sophisticated and complex instrument, and the same thing can be described in multiple  
ways. Semantic similarity is a very important tool for being able to identify which projects fall in our scope.  
Therefore, we have used AI methods in the form of the neural network (Word2Vec) to extract semantically-
related concepts. The results for AI, Health and Healthcare are shown in Box 1,2 and3. Box 1 shows the terms 
semantically related to artificial intelligence.
Box 1: Word similarity for artificial intelligence in H2020 projects
ai,  machine_learning,  big_data_analytics,  computer_vision,  deep_learning,  big_data_analysis,  analytics, 
deep_machine_learning,  big_data,  intelligence,  data_science,  nlp,  advanced_machine_learning_engine, 
advanced_artificial_intelligence,  ai)-based,  machine-learning,  data_analytics,  natural_language_processing, 
machine_learning_algorithms, data_mining, semantic_technologies, artificial_intelligence_algorithms, model-
driven_engineering,  affective_computing,  speech_recognition,  computer,  ai_algorithms,  algorithms, 
image_recognition, ml, iot, visual_analytics, machine_intelligence, question_answering, cognitive_computing, 
data-mining,  augmented_reality,  ai-based,  predictive_analytics,  information_retrieval,  ict_technologies, 
cloud_computing,  image_processing,  language_understanding,  ai_models,  ai_techniques,  ai_technologies, 
natural_language_understanding, vr/ar
As we can see, the neural network was able to extract not only AI-related words in purely mathematical  
sense, but the applications as well. If a researcher used an AI related word in the description of his/her project,  
we were able to use it even when the term ‘artificial intelligence’ was not used. 
Box 2: Word similarity for health in H2020 projects:
well-being,  wellbeing,  overall_wellbeing,  overall_health,  heath,  nutrition,  workplace_conditions,  wellness,  
lifestyle,  health_outcomes,  mental_health,  good_health,  health_status,  social_care,  social-economic, 
psychosocial,  public_health,  vital_component,  poor_health,  occupational,  life_style,  dieting,  welfare, 
overall_mobility,  lasting_consequences,  consumer_health,  health_care,  workplace,  sensory_impairment, 
later_life,  consumer_behaviours,  major_economic_burden,  women´s,  ageing_european_population, 
active_monitoring_policy,  healthy_ageing,  increasing_burden,  ageing,  reproductive_health,  older_age, 
animal_welfare, european_citizens, pets’, lifelong_health, animal_health
Again, the network returns not only the obvious. Wellbeing is mostly associated to good health but social care  
comes high in the list after health as well as welfare, healthcare and nutrition. Interesting to find economic  
burden  as related to  health,  cognitive  and sensory  impairments,  and burdens,  all  concepts  that  indicate  
health-related topics. Animal health and economic consequences are just a reminder that the health topic is 
very broad. 
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The most interesting results came for the domain of Healthcare, obviously partially overlapping with Health  
domain but fundamentally different as shown in Box 3.
Box 3: Word similarity for healthcare in H2020 projects:
health_care, medical,  vital_component, healthcare_sector, healthcare_systems, radiologic,  care, social_care, 
healthcare_products,  health-care,  clinics,  assistive_technology,  hospitals,  home_care,  consumer, 
healthcare_providers, eldercare, increasing_cost, healthcare_industry, ehealth, health, e-health, critical_care, 
mre,  eu_society,  ophthalmology,  bioelectronics_implants,  better_life,  re-treading,  medical_technology, 
personalized_healthcare, digitizing, relieves, health_care_systems, increasing_burden, health_care_providers, 
food_and_pharmaceutical_industries,  telecare,  healthcare_system,  emergency_care,  orthopedic, 
health_systems,  patient-centered,  global_healthcare_systems,  safer_products,  cancer_care,  biomedical, 
care_homes, hydrocephalus
An interesting observation is that the neural network correctly assigns eHealth to the Healthcare and not the 
Health domain. In the second step, every project has been parsed for presence of the words from the domains 
above and a score calculated as AI*HEALTH+AI*HEALTHCARE so if AI-related words were not present at all, a  
score of zero was assigned. 
As a result, we identified 146 projects on AI and Health that were also manually checked to identify any  
wrong assignment: for example, a project on cloud-computing from the AI domain and health referred not to  
human health but to health in computer uptime monitoring. Figure 13 shows the frequency of topics in the 
identified project in the period 2014-21, while Figure 14 analyses them by the country of the partners in the  
projects. 
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Figure 13: Relevant topics in AI-Health-Healthcare H2020 projects per year.
Source : Cordis data
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Figure 14: Relevant topics in AI-Health-Healthcare H2020 projects by country.
Source : Cordis data
The stronger  presence of  AI  topics,  such as  machine  learning,  and health  appears  after  2017 (Fig.  13).  
Furthermore,  it  is  visible how ‘IoT’  gained attention since 2017 (in  orange in  the  figure).  Concerning the  
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geographical distribution (Fig. 14), the strongest cluster of concepts (in orange in the figure), is related to 
projects with partners in Germany, Belgium, Italy, Greece, France, Spain, the Netherlands and the UK.
The emergence of topics such as ‘IoT’ and ‘robotics’ appears also when analysing H2020 projects related to 
health  in  general.  To  this  end,  we  have  selected  4916  projects  containing  the  word  "health"  from  all 
the 30902 projects  funded under H2020 programme. To understand how the projects  group together  by  
semantic  similarity,  we  have  calculated  sentence  embedding  for  all  projects'  titles  and  objectives  using 
SciBERT transformer fine-tuned on natural language inference tasks. The resulting latent space was projected 
using UMAP algorithm and clustered in HDBSCAN. We obtained groups that,  besides human health,  span 
ecosystem health, economic health, animal health and system health.
Focusing on human health, we have identified 30 major groups of H2020 projects in the domain of human 
health and health care.  In Fig. 15, each project is counted for every year it runs and it is possible to observe 
‘health IOT’ and “medical robotics” gaining traction after 2017.
Figure 15: Topic clusters in H2020 on health. 
Source : Cordis data
Going deeper in the analysis of the original cohort of 146 projects in AI and health, Spain and Germany lead 
in coordinating projects, with 28 and 26 projects respectively, followed by the UK and Italy, with 17 and 11  
projects respectively (Fig. 16 left). In terms of timeline, 2017 marked the start of the take up in number of  
projects, peaking in 2019 with 53 starting projects, more than double that of 2018 (Fig. 16 right). As indicated 
the number for projects due to start in 2020 and 2021 is provisional.
26
Figure 16: Distribution of AI and Health projects 
per (left) coordinator country and (right) per year.
Source : Cordis data 
Note: number of projects in 2020 and 2021 are provisional
On the financial side, the project funding follows a different pattern, both for geographical distribution and 
timeline: for this latter aspect, the aggregated funding per year remained relatively steady in the 2017-2020 
period, its lowest point being in 2018 with approximatively 71 million EUR and its peak in 2019, with around  
122 million EUR. Interestingly, in 2020 the funding already amounts to around 108 million EUR, which is  
already very close to the 2019 figure (Fig. 17 right) even though the figures on the projects are not yet  
complete. The geographical distribution of funding (Fig. 17 left) shows that Spain and the Netherlands lead,  
with around 82 million EUR (for 28 projects) and 81 million EUR (for 10 projects) respectively, followed by  
Germany and Italy, to which 60 million EUR (for 28 projects) and 52 million EUR (for 11 projects) have been  
allocated. The value added of European R&D funding is illustrated well by the case of BioNTech spotlighted in  
Box 4.
Figure 17: Distribution of AI and Health project spending 
per (left) coordinator country and (right) per year.
Source: Cordis data. Note: number of projects in 2020 and 2021 are provisional
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Box 4. Vaccine against COVID-19 enabled by EU-funded research and AI made in Europe 
At the beginning of November 2020, Pfizer and Biopharmaceutical New Technologies (BioNTech) announced 
that their mRNA-based vaccine demonstrated evidence of efficacy against COVID-19. Whereas Pfizer is a well-
known multinational biopharmaceutical company, BioNTech has not been at the centre of public attention until 
recently.  Founded in 2008, BioNTech is a spin-off of the Johannes Gutenberg-University Mainz,  Germany. 
Today,  with  over  €20 bn.  of  market  capitalisation and over  1300 employees3,  it  belongs  to  the  club  of 
European deep-tech unicorns and develops novel RNA-based technologies that are used to fight COVID-19.  
BioNTech is an example of a company that integrates Artificial Intelligence (AI) technologies in traditional 
industries. Discovering and developing new drugs and setting up a production and supply system providing 
hundreds of thousands of patients with personalized medications requires the development and convergence 
of innovations in a range of different advanced technologies, such as big data, artificial intelligence, and fully  
automated analytics and production lines. To this aim, BioNTech uses both proprietary Artificial Intelligence 
(AI) technology platforms and AI solutions provided by small and large European ICT firms. The research of  
BioNTech has benefited from the European support for research and innovation since its early days. Until  
today, BioNTech and its subsidiaries have participated to ten EU Framework Programme projects and received 
nearly 10 M. Euro of funding. As early as in 2009, the German start-up participated to the PERSIST FP7 
project where it explored the use of highly innovative gene-modifying in developing new therapies.4 In 2013, it 
set-up and coordinated the MERIT FP7 project aiming at clinically translating and industrially validating the 
pioneering RNA-based immunotherapies. According to the MERIT project proposal, BioNTech and its partners 
were committed to generate scientific knowledge and technologies that would stimulate the development of 
new mRNA-based products, tools, patents, and innovative marketable applications. Today, we can say that the  
EU-supported project lived up to its promise. Its results have contributed to the creation of a remedy to a  
disease that has paralysed the entire world. 
6. Industry
6.1 Overview of uptake
There is strong interest in AI and related technologies in the commercial sector in Europe as detected by a  
recent survey of almost 10,000 companies in Europe, mostly SMEs, carried out on behalf of the European 
Commission in 2020 (IPSOS, 2020). The key findings are that across all sectors, including health, 42% of  
companies are already using one or more AI solutions, with an additional 18% planning to adopt within two 
years,  while  the  remaining  40%  indicated  that  they  have  not  implemented  or  have  no  intention  of 
implementing AI-based solutions in the near future.  We see therefore a high level of interest but with a 
significant  minority  yet  to  be  convinced.  This  is  important  to  ground  the  discussion  which  is  often 
characterised by hype and inflated expectations (Topol, 2019a). 
6.2 Patents
In order to get insights into the technological innovation flow, we analysed a comprehensive patents database, 
mined using Orbit  Intelligence software by Questel.  This  database covers the  World  Intellectual  Property  
Organization (WIPO), the European Patent Office (EPO) and the national authorities in UK, Canada, France, 
Germany, China, Japan, South Korea and India, totalling over 100 patents authorities.
The database records come in the form of ‘FamPat family numbers’: such families of patents are invention-
based collating together  all  the  publication  stages of  an  invention as  well  as  documents  from different 
patenting authorities.
In the database, we filtered for patents featuring both AI-related and healthcare-related keywords, obtaining 
46036 results5 which represent the 1.75% of the records mined with just healthcare related keywords (N= 2 
619 216).
In our analysis, we also considered the distinction between patents and utility models6 : the latter type of 
invention protection differs from the patents in duration (they are usually shorter, between 6-10 years), faster  
3https://www.wallstreet-online.de/aktien/biontech-1-aktie
4https://cordis.europa.eu/project/id/222878
5 As per 6/7/2020.
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and cheaper to obtain. Furthermore, the degree of innovation carried by the invention is generally lower for a 
utility model and, according to the specific country regulation, it may be absent altogether.  Another important 
difference with patents is that they can be granted without a search for previous similar patented invention.
Utility models are a protection tool present in many countries, such as Germany, France, Japan and China, but  
only China makes a widespread use of them. According to the WIPO7,  the total  number of utility model 
applications worldwide reached 1.76 million in 2017. The IP office of China received 95.8% of the world total  
– the remaining 74 offices accounted for just 4.2%.
Similarly, our dataset of AI and health applications dropped by 18% to 37673 results when removing Chinese  
utility  models.  Conversely,  all  the  other  countries’  utility  models  contributed  to  only  177  results8, 
approximatively the 0.4% of the dataset. Hence, in the following analysis we differentiate between numbers 
with or without Chinese utility models.
The number of applications for inventions (Fig. 18 left) in the healthcare and AI nexus has seen a substantial  
increase since 2013.  China dominates in the number of patents (Fig. 18 right) with 22129, which reach  
30492 when including the utility models. US is second with 10735 and WIPO is third with 9173 patents (in Fig 
14, under ‘WO’).
Figure 18: Year of first application and country of patents in AI and health/healthcare
Note: The data for 2019 and 2020 are to be considered provisional because of the 18-months gap between the filing of an application 
and its publication. As a patent family may cover several publication documents for the same invention, it may therefore be counted in 
several columns.
Source: based on data from Questel
Having a closer look at the top players (Fig. 19), both with and without utility models from China, the South  
Korean Samsung Electronics  appears  to  dominate  by  far  the  field  with  over  1400  patents,  followed  by 
Siemens Healthcare with around 300. However,  as we show in Fig.  22,  Samsung patents mostly concern 
applications and protocols for smart IOT devices, that can be used in healthcare context but they are not  
specific to it.
The difference, when removing utility models, is visible in the bottom half of the ranking, with some Chinese  
universities and companies losing position, as for example the South China University of Technology, while 
others rank higher such as Tencent Technology.
6 A comprehensive description can be found on the WIPO website 
https://www.wipo.int/patents/en/topics/utility_models.html
7 https://www.wipo.int/edocs/pubdocs/en/wipo_pub_941_2018-chapter2.pdf , pag. 33 and pag. 63 fig. A55.
8 Worldwide breakdown of utility models as per 13/7/2020:  DE: 80, KR: 74, JP: 17, FR: 3, BR: 2, PT: 1, DK,MD,AU,CR: 0.
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Figure 19: Top-20 patents assignees with (top) and without (bottom) Chinese utility models in the 
period 1980 - 2020.
Source: based on data from Questel
Cooperative  Patent  Classification  (CPC)  and  International  Patent  Classification  (IPC)  codes  allow  better 
understanding of the patented inventions themselves (Figs. 20-21). Instruments for medical procedures and 
health care informatics are the dominant classes for CPCs, with about 6000 patent families each, followed by 
data processing systems (Fig. 20).
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Figure 20: Patents distribution according to the CPC subclasses.
Source: based on data from Questel
However, as CPC codes are a harmonization of classification codes by the European Patent Office and the 
United States Patent and Trademark Office and they have only recently been introduced in China and Korea9, 
we also contrasted the distribution in CPC codes with the one of the International Patent Classification (IPC) 
(Fig. 21). In this case, the dominant class, by far,  is instruments for medical procedures, featured in over 
20,000  patent  families,  followed  by  preparations  for  medical  purposes  and  electrical  and  digital  data 
processing, both featured by around 12,000 patent families. Interestingly, the healthcare informatics moves 
into fourth position with around 9,485 citations, while it was first in the distribution based on CPC codes.
Figure 21: Patents distribution according to the IPC subclasses.
Source: based on data from Questel
9China and Korea agreed to start introducing the CPC system from 2013.
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IPC codes allow for a clearer breakdown of Samsung Electronics patents which, as previously noted, concern 
mostly protocols and application for IOT devices and they are not specifically geared towards health (Fig. 22).
Figure 22: Patents distribution according to the IPC subclasses for Samsung Electronics (log10 
scale).
Source: based on data from Questel
6.3 Venture Capital Investments
Another facet of industrial take-up, venture capital investments, was analysed leveraging a dataset provided 
by Dealroom10 of 37504 companies active in the health/healthcare domains. Founded in 2013, Dealroom is  
an  Amsterdam-based  data  and  software  platform,  which  provides  worldwide  intelligence  on  startups, 
innovation and venture capital investment. Dealroom data is used to search and compare the performance 
characteristics of innovative companies, generate reports and track industry trends. Dealroom data has been 
extensively used for monitoring the developments of the European start-up landscape (Fig. 23). For example,  
funded in 2020 with the support of the European Commission and European Parliament, European Startups 11 
is a project aimed at facilitating informed conversation and collaboration among European tech ecosystem 
stakeholders to help to develop Europe’s startup economy. European Startups is entirely based on Dealroom 
data.
Figure 23: Global venture capital invested, 1995-2020
 
Source: Dealroom.co. Note: 2020 is annualized based on Jan – Oct.
10 https://app.dealroom.co/
11 https://europeanstartups.com
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For our analysis, we filtered in the health related dataset the companies with funding compatible with being a 
startup12,  giving a first  cohort  of 13199 companies.  Furthermore,  we mined the companies featuring AI-
related  keywords  in  their  description  to  isolate  a  subset  of  1917  AI  companies  from the  total.  At  the 
intersection between these two subsets, we found 1071 companies featured both in the startup cohort and in 
the AI one. 
As shown in Fig. 24, venture capital (VC) investments in health-related startup companies have seen a rapid  
growth, especially steep after 2014. The percentage of such investments directed towards AI related startups 
has also increased, passing from ~7% in 2014 to around 14% in 2017. Many of the VC investments in AI-
enabled health start-ups are in the area of drug discovery, i.e. the domain of BioNTech (see Box 4).
Figure 24:  Global venture capital investments on startups aggregated over the years and the 
percentage of capital invested in AI related startups.
Source: based on data by Dealroom
The geographical distribution of investments in Fig. 25 shows that the US and Canada hold the lion’s share, 
with ~73% of the total VC capital directed towards health startups (green bar in the figure) and AI & health  
receiving 62% of such investments (blue bar in figure). Europe follows with much smaller figures: 14.40% of 
total  VC investments concerning health startups and 19.33% of these investments going to AI  & health  
startup companies.
Figure 25:  Venture capital investments on startups per region.
Source: based on data by Dealroom
Deepening our analysis of the dataset, we mined the websites of a subset of companies, randomly chosen,  
corresponding to about 10% of the original set (3511 companies).  We clustered the companies’  website  
12 More in detail, companies whose funding rounds were of the type : 'angel',  'seed',  'early vc',  'series a-i', 'late vc',  
'growth equity'.
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descriptions in an unsupervised manner according to their similarity, so that similar companies were clustered  
together, highlighting the presence of five main groups as shown in Fig. 26..
Figure 26: Communities of similar companies in health and healthcare. 
Source: JRC based on data from Dealroom.. 
Note: Sample of size N=3511. The dots’ sizes are proportional to their degree (i.e. the number of connections), the tags are the most 
frequent bigrams (i.e. couple of adjacent words) shared by the companies.
In Fig. 26, we can observe three tightly knit clusters, composed of companies similar to each other with many  
linkages. These clusters are thus relatively uniform and concern clinical trials and research (in purple), medical  
centres and healthcare providers (in green) and healthcare data and service providers (in grey).
The blue cluster concerns very specific clinical applications, such as dental and skin care. Since the companies 
in this cluster are more heterogeneous, they have very few connections (thus the small size of the blue dots in 
the figure) and the cluster is spread at the rim of the aforementioned three main clusters. Last but not least,  
the small but densely connected orange cluster concerns medical devices.
Within each cluster, we isolated the companies working with AI-related technologies which are, proportionally,  
more present in the ‘Medical devices’ cluster, totalling 8.3% of the companies in the cluster. On the other 
hand, the remaining four clusters have a much smaller percentage of AI presence, ranging from 1.1% to 2.4% 
(Fig. 27 left). As a last step, we filtered with the above criterion, which of the AI related companies were also  
startups (Fig. 27 right) and the ‘Medical devices’ class still leads proportionally to its size, with 3.5% of AI  
startups. The high proportion of AI technologies in the medical devices’ class is unsurprising as AI software for 
healthcare applications is legally considered as a medical device and it is vetted as such.
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Figure 27: Percentage of (top) AI-related companies and (bottom) AI-related startups within each 
cluster, normalized to each cluster’s size.
Source: JRC based on data from Dealroom
7. Local and hospital scale initiatives
The deployment of AI applications requires going beyond the proof-of-concept stage to the validation in real-
world setting (Topol,  2019b,  Topol,  2019a).  Field testing AI  applications at the hospital  or regional  level,  
especially in terms of data access and domain knowledge transfer is therefore crucial. A real-world setting is  
also likely to shed light on unforeseen issues: a well-known case was IBM Watson for Oncology that often 
made the wrong recommendations for cancer treatment, for instance recommending a drug conflicting with a 
patient’s pre-existing morbidity (Ross, 2018). In this case, the flaw stemmed from the paucity of real input 
data, giving a practical example of why repeated trials in the medical practice are so fundamental for a  
proper  vetting.  This  approach,  rounds  of  debugging  through  actual  use  leading  to  a  stable  version,  is  
customary in software development and it should be all the more so for AI applications in health care.
In  more  general  terms,  hospital  scale  deployment  could  embody  an  implementation  of  the  “innovation 
sandbox” concept presented by the authors of the Villani mission report on the AI strategy for France (2018).  
In their view, the advantages of such closed environments would be threefold: firstly, provide a fertile ground 
for experimentation in real-world conditions, second, they could familiarize the actors involved, e.g. clinicians  
but also computer scientists, with new duties and responsibilities. Lastly, a sandbox could (temporarily) benefit 
from less tight regulation constraints to foster innovation further.
Facing the COVID-19 burden, several hospitals started adopting AI solutions to deliver care at scale. As an  
example, the Providence St. Joseph Health system used an online screening to facilitate pre-hospital triage  
distinguishing  potential  COVID-19  patients  from  the  ones  with  less  severe  pathologies.  As  a  clinical 
application, radiologists at the Zhongnan Hospital in Wuhan, China, were assisted by an AI classifier which, 
detecting the disease from CT scans, could help isolating Covid-19 patients. Similarly, in Europe, the French 
teleradiology firm Vizyon uses an algorithm to unveil the onset of COVID-19 in chest X-rays, made by the 
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Korean firm Lunit, and teamed up with the Centre Médical Europe for its deployment13; while a classifier for 
chest X-rays, developed by Mumbai-based Qure.ai, is used at the San Raffaele Hospital in Milan.14.
As we mentioned previously, AI products pertaining to the clinical side are less mature than the ones tackling 
operational, financial and administrative tasks. The American Hospital Association (AHA, 2019b) analyses in 
depth this point, highlighting how through the streamlining of such tasks it could be possible to deliver a  
higher quality care by an improved time management. An example of this already possible automation could  
be obtaining prior authorizations from insurances for specific medical procedures.
The benefits of a limited and controlled deployment of an AI product at hospital level do not come without 
challenges. A recurring theme is the “fear of replacement” (Polton, 2018, NHS, 2018) expressed by the health  
care workforce with respect to AI.  For its mitigation, training and exposure to data science practices is a 
necessary future step along with, in the long run, the creation of new professional roles, as we shall discuss in  
the next section.
8. Examples of national and European governmental scale initiatives
The scaling up  of  Ai  application  requires nationwide initiatives  tackling the  consolidation of  health  data. 
Europe, can leverage large nationwide health systems and several countries have already started to design 
strategies to use the richness of the data available (McKinsey, 2020).
France, for example, has created the Health Data Hub (HDH, 2018) and, in 2016, the SNDS (Système National 
des Données de Santé)  for  the exploitation of medical  data.  The SNDS tries to overcome the traditional  
fragmentation of  existing datasets15:  It  collates data from medical  prescriptions,  financial  data from the 
hospitals  and causes  of  death from different  systems.  Furthermore,  it  plans  to  incorporate  the  regional 
databases concerning handicapped citizens and, finally, a sample of private insurance reimbursement data 
(HDH, 2018). This wealth of data, following some 60 million French citizens, is not, however ‘AI ready’ (Polton, 
2018): such datasets were conceived for administrative purposes, and thus require additional work to extract 
clinical information. Nevertheless, the SNDS is  very rich data source spanning over 20 years. 
The use of these datasets is regulated by the Health Data Hub which grants access to the anonymised data,  
processing  the  requests  and  assessing  their  eligibility  together,  if  needed,  with  the  CNIL  (Commission 
Nationale de l’Informatique et des Libertés).  This  lightweight approach produced,  during the first  year of 
operation (2017-2018), an average of 70 days waiting time for approval when vetting from the CNIL was  
required (HDH, 2018), which represents a considerable improvement from the 3-6 months waiting time in the  
previous system.
Similarly, in UK, the Health Data Research UK (HDR UK) Institute, established in April 2018, provides access to 
health datasets through the HDR Innovation Gateway, gathering more than 500 datasets, along with tools for 
data analysis and a community forum. Furthermore, HDR features eight Hubs, which are collaborations with 
patients, UK Universities, third sector, government organisations and industry, either geared towards a specific 
group of ailments, such as cancer and respiratory diseases, or towards improving processes, such as care  
delivery.  Beyond research building on health data,  the HDR UK outlined plans also focused on education, 
aiming to train 10000 health data scientists over the next five years (HDR, 2019).
At the European level, the European Commission already identified health in its Communication on AI (EC, 
2018a) as a sector where Europe has world-leading industry and a wealth of industrial, research, and public 
sector data.  The richness of this data is the focus of the European Strategy for Data that envisages the 
establishment of several thematic data spaces, of which one on health to support “advances in preventing,  
detecting and curing diseases as well as for informed, evidence-based decisions to improve the accessibility, 
effectiveness and sustainability of the healthcare systems” (EC, 2020a).  The strategy builds on the 2018 
Communication on eHealth (EC, 2018b) and envisages both sector-specific legislation including greater access 
to and portability of personal health data by citizens, dedicated infrastructures and analytical tools, and the 
development  and  interoperability  of  national  electronic  health  records.  Other  important  forthcoming 
developments are the launch in 2021 of the Horizon Europe R&D programme as well  the Digital  Europe 
Programme with large investments in AI, computing infrastructure, cybersecurity and training. The COVID-19 
crisis has also acted as a booster to the adoption of AI in health and the digital  transition of business,  
research,  education  and  public  administration  (Craglia  et  al.  2020).  Furthermore,  the  unprecedented 
13https://www.technologyreview.com/2020/04/23/1000410/ai-triage-covid-19-patients-health-care/
14https://www.business-standard.com/article/technology/how-a-mumbai-start-up-is-helping-italian-doctors-test-covid-19-
patients-120040700994_1.html
15 https://www.indsante.fr/fr/les-composantes-du-snds 
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investments of the Recovery Plan agreed in July 2020 may fuel development in digital  technologies and 
health beyond expectation.
Last but not least, a key issue for the adoption and use of AI methods in health and healthcare is the training  
of the healthcare workforce to master the use of AI products and help their development. In this respect,  
several reports (AHA19a; Topol 2019b; Health Data Hub, 2018) discuss at length the need for such education,  
both in the form of upskilling the existing workforce and through the creation of new professional figures. For 
example, in France, the Health Data Hub (2018) foresees the introduction of a data science course in the 
medicine curriculum and, in the UK, Health Education England is developing a portal for the NHS to foster 
digital  education16.  Similarly,  the  Technion  Israel  Institute  for  Technology  has  launched a  double  degree, 
leading to a BSc in Medicine and Computer Science (McKinsey, 2020), which would then be followed by clinical  
school  to  form practitioners  who  also  possess  a  deep  understanding  of  computer  science.  These  early  
examples show the increasingly recognised importance of introducing AI in the education and training of  
healthcare  professionals.  A  similar  conclusion  was  reached  by  the  High-Level  Expert  Group  on  Artificial 
Intelligence (HLEG, 2020). The group recommended on the one hand the establishment of mechanisms to 
make AI developers knowledgeable of health-related issues and, on the other to pay particular attention to 
the  reskilling  and upskilling  of  health  practitioners  so that  they  are  better  equipped  to  understand  and  
challenge AI-generated advice.
9. Conclusions
In  this  report,  we have explored the  different  facets  of  the adoption of  AI  in  the health and healthcare  
domains,  drawing observations from several datasets and bibliographical sources. In this last section, we 
summarize the key results to be revisited in future editions of this report to see how the domain has changed,  
in line with the mission of AI Watch. 
In Section 2 we noted that while the analysis of the global AI landscape shows Europe behind the USA but 
ahead of China, when it comes to the health and healthcare domains, China is the leading player followed by  
Europe and the USA. The characteristics of the three regions are however distinctively different. While the USA 
is dominated by commercial firms with relatively few pure research players, in China about one third of the  
players are research institutes, rising to almost two thirds in the EU27. This confirms the very strong research  
vocation of the EU, and the key role also played by the European R&D programme. In terms of areas of 
specialisation, the EU and the USA are comparable, while China has a strong dominance in the technologies  
and methods for diagnostics which include image recognition where China has a strong worldwide lead. As 
detailed in Craglia et al. (2018) the AI ecosystem in China is characterised not only by a young population  
eager  to  adopt  innovations,  and  a  wide  spectrum  of  innovative  companies,  but  also  by  the  strong 
governmental support for companies through favourable economic and regulatory conditions, and a multiple 
role as strategic investor, consumer of digital technologies, and provider of access to key data. The state 
control on user data has been key in developing the lead in facial recognition technology which then supports  
the lead in diagnostic medical technology we detect in this report. As Europe has a very varied and rich set of  
health-related data it is potentially in a very strong position and the development of a European common 
space for health data is a very promising initiative. 
Section 3 reviewed the technology availability level of AI in medicine and healthcare and their potential social  
impacts. These ranged from the very positive for computer-aided diagnosis and workflow efficiency to the 
controversial for merging medical and social data and social engineering, to the distinctively negative for  
bioterrorism, biohacking with evil intent and the weaponization of AI. The Section which builds on an extensive 
review of over 600 sources by Gómez-González and Gomez (2020) helps to highlight both opportunities and 
challenges of AI applications in this domain. How to guide the development and grasp the opportunities while 
reducing the risks to the minimum is a key issue, and one that is being addressed in Europe through the  
proposal for a risk-based regulatory framework for AI (EC, 2020b).
Section 4 analysed the scientific medical literature observing a definite increase (although from a low base) of 
interest in AI and healthcare in the period 2012-2014 and since 2018, accelerating further as a result of the 
COVID-19 pandemic in 2020.  This interest towards the AI and health nexus is mirrored by the analysis of 
H2020 projects in Section 5 where we observe a stronger growth in health and healthcare projects since 2015 
and, in combination with AI, since 2017.
16 https://www.hee.nhs.uk/
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The industrial sector,  investigated by the means of patents (Section. 6.2) and venture capital investments 
(Section 6.3) follows closely the timeline set by scientific publications. For patents, the number of applications  
filed started to rise steeply after 2012 and its pace increased after 2014. In terms of countries, China and USA 
are the major  contributors,  although,  as discussed,  China makes an extensive use of a  “lighter”  form of 
patents,  called  utility  models.  Utility  models  correspond  to  less  mature  and  potentially  less  innovative 
products because of less stringent requirements, and, in China’s case, correspond in our data to roughly a 
third of the applications filed. 
The distribution of companies holding the majority of patents is led by the Korean giant Samsung Electronics,  
whose patents however are mostly directed towards smart IOT at large that can also be used for health-
related devices rather than patents targeting health specifically. Siemens Healthcare, IBM, and Philips follow 
Samsung, marking a strong European presence in the top four patents holders. 
Finally, the percentage of venture capital (VC) investment directed towards AI and health startups rose from  
2-3% in 2012 to 15% in 2017. In this case, North America and Europe are the major players, with however 
very different patterns, as the former represents around 74% of VC investment on health startups against 
14% in Europe. There is a strong difference also in the proportion of such investments devoted to AI and 
health startups: of the total VC investment in health startups, around 65% in the USA and Canada is directed  
towards startups on both AI and health against 19% for Europe.
Overall, the data shows that AI in health and healthcare is a field undergoing a fast expansion but is still  
relatively small. For example, relevant H2020 projects account for only 0.5% of the total number of R&D 
projects while AI-related patents are less than 2% of the total of health patents. Notwithstanding this low 
starting point, the report highlights three trends likely to strengthen in the coming years:
1. Short term: Adoption of AI applications for operational improvements.
AI technologies can be at very different stages of maturity. At the present time, applications streamlining 
workflow processes are  the  most  promising as they  are  based on mature technologies  and applications 
already available in other industrial sectors as indicated by American Hospital Association (2019b; NHS, 2018, 
and McKinsey, 2020) 
2. Medium term:  Availability and interoperability of health data.
The quality of AI models critically depends on large volumes of good quality, semantically-structured data,  
labelled to provide also information-rich context. Therefore, a necessary step in the medium term to boost the  
adoption of AI in health and healthcare is the creation of shared repositories of health data at the national 
and European level, as envisaged by the European strategy for data (EC, 2020a).  The challenges are many as 
data is currently fragmented in many repositories, with different formats and definitions, and bringing the 
data together faces regulatory challenges as recognized also by the report of the High-Level Expert Group  
(HLEG, 2020). European health systems are nevertheless among the best in the world with respect to the 
richness and diversity of data available, so the opportunity for Europe to become world leader but above all to 
bring tangible benefits to European society is here to be grasped. Because European health data is so rich, we 
need  also  to  be  conscious  that  it  attracts  considerable  interest  from  non-European  players,  so  data 
sovereignty and security  of the  European data spaces is  crucial.  The strong political  commitment  to the 
development of a common European data space for health as a key pillar of a forthcoming European Health 
Union was reiterated by European Commissioner Kyriakides and Germany’s Federal Minister of Health Spahn 
at  the Digital  Health  conference17 held on the 11th November 2020.  An initial  step in  this  direction was 
presented  by  Estonian  President  Kaljulaid  who  indicated  that  at  least  in  the  area  of  e-prescriptions  an 
interoperable data space has already been established between Estonia, Finland, and Portugal. 
3. Long term:  Empowering the healthcare workforce.
The development and effective use of AI technologies in health and healthcare needs a strong partnership  
across disciplines: for computer scientists to work with health practitioners and understand their needs, and  
for health practitioners to acquire digital skills and, in the long run, even become familiar with data science as  
part  of  their  education  and  training,  so  that  they  can  be  empowered  to  shape  the  direction  of  the 
development  of  application  as  well  as  challenge  products  coming  onto  the  market.  To  this  end,  as 
recommended  by  the  High-Level  Expert  Group  on  AI  (HLEG,  2020),  upskilling  the  existing  workforce  by  
providing an environment for education and training, and creating environments for multi-disciplinary dialogue 
are fundamental enablers for AI uptake in health and healthcare systems. 
17https://hlc2020.de/programme and   
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The purpose of this report as outlined in the introduction was to set a benchmark against which we can  
measure change in the adoption, use, and impact of AI in health and healthcare. From this point of view,  
finding that we are at a relatively early stage of AI adoption means we are in a better position to shape future  
directions exploiting the many opportunities for European society and reducing the potential risks. 
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